144 related articles for article (PubMed ID: 38434938)
1. Dynamic evolution of the sofosbuvir-associated variant A1343V in HEV-infected patients under concomitant sofosbuvir-ribavirin treatment.
Gömer A; Dinkelborg K; Klöhn M; Jagst M; Wißing MH; Frericks N; Nörenberg P; Behrendt P; Cornberg M; Wedemeyer H; Steinmann E; Maasoumy B; Todt D
JHEP Rep; 2024 Mar; 6(3):100989. PubMed ID: 38434938
[TBL] [Abstract][Full Text] [Related]
2. Emergence of resistance-associated variants during sofosbuvir treatment in chronically infected hepatitis E patients.
Gömer A; Klöhn M; Jagst M; Nocke MK; Pischke S; Horvatits T; Schulze Zur Wiesch J; Müller T; Hardtke S; Cornberg M; Wedemeyer H; Behrendt P; Steinmann E; Todt D
Hepatology; 2023 Dec; 78(6):1882-1895. PubMed ID: 37334496
[TBL] [Abstract][Full Text] [Related]
3. Ribavirin Treatment Failure-Associated Mutation, Y1320H, in the RNA-Dependent RNA Polymerase of Genotype 3 Hepatitis E Virus (HEV) Enhances Virus Replication in a Rabbit HEV Infection Model.
Wang B; Mahsoub HM; Li W; Heffron CL; Tian D; Hassebroek AM; LeRoith T; Meng XJ
mBio; 2023 Apr; 14(2):e0337222. PubMed ID: 36809085
[TBL] [Abstract][Full Text] [Related]
4. Ledipasvir/sofosbuvir and ribavirin for the treatment of ribavirin-refractory persistent hepatitis E virus infection.
Gallacher J; Taha Y; da Silva Filipe A; Ijaz S; McPherson S
IDCases; 2023; 32():e01741. PubMed ID: 36942308
[TBL] [Abstract][Full Text] [Related]
5. In vivo evidence for ribavirin-induced mutagenesis of the hepatitis E virus genome.
Todt D; Gisa A; Radonic A; Nitsche A; Behrendt P; Suneetha PV; Pischke S; Bremer B; Brown RJ; Manns MP; Cornberg M; Bock CT; Steinmann E; Wedemeyer H
Gut; 2016 Oct; 65(10):1733-43. PubMed ID: 27222534
[TBL] [Abstract][Full Text] [Related]
6. High dose sofosbuvir and sofosbuvir-plus-ribavirin therapy inhibit Hepatitis E Virus (HEV) replication in a rabbit model for acute HEV infection.
Liang Z; Shu J; He Q; Zhang F; Dai L; Wang L; Lu F; Wang L
Antiviral Res; 2022 Mar; 199():105274. PubMed ID: 35247472
[TBL] [Abstract][Full Text] [Related]
7. Autochthonous acute hepatitis E: treatment with sofosbuvir and ribavirin.
Biliotti E; Franchi C; Spaziante M; Garbuglia AR; Volpicelli L; Palazzo D; De Angelis M; Esvan R; Taliani G
Infection; 2018 Oct; 46(5):725-727. PubMed ID: 29946850
[TBL] [Abstract][Full Text] [Related]
8. Antiviral Candidates for Treating Hepatitis E Virus Infection.
Netzler NE; Enosi Tuipulotu D; Vasudevan SG; Mackenzie JM; White PA
Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30885901
[TBL] [Abstract][Full Text] [Related]
9. Sofosbuvir add-on to ribavirin for chronic hepatitis E in a cirrhotic liver transplant recipient: a case report.
Fraga M; Gouttenoire J; Sahli R; Chtioui H; Marcu C; Pascual M; Moradpour D; Vionnet J
BMC Gastroenterol; 2019 May; 19(1):76. PubMed ID: 31126238
[TBL] [Abstract][Full Text] [Related]
10. Sofosbuvir (Sovaldi°). Active against hepatitis C virus, but evaluation is incomplete .
Prescrire Int; 2015 Jan; 24(156):5-10. PubMed ID: 25734194
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of ultra-short, response-guided sofosbuvir and daclatasvir therapy for hepatitis C in a single-arm mechanistic pilot study.
Flower B; Hung LM; Mccabe L; Ansari MA; Le Ngoc C; Vo Thi T; Vu Thi Kim H; Nguyen Thi Ngoc P; Phuong LT; Quang VM; Dang Trong T; Le Thi T; Nguyen Bao T; Kingsley C; Smith D; Hoglund RM; Tarning J; Kestelyn E; Pett SL; van Doorn R; Van Nuil JI; Turner H; Thwaites GE; Barnes E; Rahman M; Walker AS; Day JN; Chau NVV; Cooke GS
Elife; 2023 Jan; 12():. PubMed ID: 36622106
[TBL] [Abstract][Full Text] [Related]
12. High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world.
Pérez AB; Chueca N; García-Deltoro M; Martínez-Sapiña AM; Lara-Pérez MM; García-Bujalance S; Aldámiz-Echevarría T; Vera-Méndez FJ; Pineda JA; Casado M; Pascasio JM; Salmerón J; Alados-Arboledas JC; Poyato A; Téllez F; Rivero-Juárez A; Merino D; Vivancos-Gallego MJ; Rosales-Zábal JM; García F;
J Hepatol; 2019 Nov; 71(5):876-888. PubMed ID: 31279901
[TBL] [Abstract][Full Text] [Related]
13. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial.
Lawitz E; Poordad FF; Pang PS; Hyland RH; Ding X; Mo H; Symonds WT; McHutchison JG; Membreno FE
Lancet; 2014 Feb; 383(9916):515-23. PubMed ID: 24209977
[TBL] [Abstract][Full Text] [Related]
14. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study.
Molina JM; Orkin C; Iser DM; Zamora FX; Nelson M; Stephan C; Massetto B; Gaggar A; Ni L; Svarovskaia E; Brainard D; Subramanian GM; McHutchison JG; Puoti M; Rockstroh JK;
Lancet; 2015 Mar; 385(9973):1098-106. PubMed ID: 25659285
[TBL] [Abstract][Full Text] [Related]
15. Whole genome sequencing reveals insights into hepatitis E virus genome diversity, and virus compartmentalization in chronic hepatitis E.
Melchert J; Radbruch H; Hanitsch LG; Baylis SA; Beheim-Schwarzbach J; Bleicker T; Hofmann J; Jones TC; Drosten C; Corman VM
J Clin Virol; 2023 Nov; 168():105583. PubMed ID: 37716229
[TBL] [Abstract][Full Text] [Related]
16. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation.
Charlton M; Gane E; Manns MP; Brown RS; Curry MP; Kwo PY; Fontana RJ; Gilroy R; Teperman L; Muir AJ; McHutchison JG; Symonds WT; Brainard D; Kirby B; Dvory-Sobol H; Denning J; Arterburn S; Samuel D; Forns X; Terrault NA
Gastroenterology; 2015 Jan; 148(1):108-17. PubMed ID: 25304641
[TBL] [Abstract][Full Text] [Related]
17. Pre-existing, treatment-specific resistance-associated substitutions in hepatitis C virus genotype 1 and 3 and viral RNA titers during treatment with direct-acting antivirals.
Sølund C; Pedersen MS; Fahnøe U; Filskov J; Jenssen H; Weis N; Schønning K; Bukh J
APMIS; 2023 Aug; 131(8):426-433. PubMed ID: 37355962
[TBL] [Abstract][Full Text] [Related]
18. Successful treatment of HBV, HCV, & HEV, with 12-week long use of tenofovir, sofosbuvir, daclatasvir, and ribavirin: A case report.
Wahid B
J Infect Public Health; 2020 Jan; 13(1):149-150. PubMed ID: 31235341
[TBL] [Abstract][Full Text] [Related]
19. Resistance-associated substitutions and response to treatment in a chronic hepatitis C virus infected-patient: an unusual virological response case report.
Aldunate F; Echeverría N; Chiodi D; López P; Sánchez-Cicerón A; Soñora M; Cristina J; Moratorio G; Hernández N; Moreno P
BMC Infect Dis; 2021 Apr; 21(1):387. PubMed ID: 33902462
[TBL] [Abstract][Full Text] [Related]
20. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial.
Mizokami M; Yokosuka O; Takehara T; Sakamoto N; Korenaga M; Mochizuki H; Nakane K; Enomoto H; Ikeda F; Yanase M; Toyoda H; Genda T; Umemura T; Yatsuhashi H; Ide T; Toda N; Nirei K; Ueno Y; Nishigaki Y; Betular J; Gao B; Ishizaki A; Omote M; Mo H; Garrison K; Pang PS; Knox SJ; Symonds WT; McHutchison JG; Izumi N; Omata M
Lancet Infect Dis; 2015 Jun; 15(6):645-53. PubMed ID: 25863559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
